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Background: Friedreich’s ataxia (FRDA) is the most common autosomal recessive
ataxia. Disease-modifying treatments are not available yet; however, several compounds
are currently under investigation. As a result, there is a growing need for the identification
of robust and easily accessible biomarkers for the monitoring of disease activity and
therapeutic efficacy. The simultaneous measurement of multiple brain-derived proteins
could represent a time- and cost-efficient approach for biomarker investigation in
pathologically complex neurodegenerative diseases like FRDA.
Objectives: To investigate the role of plasma neurofilament-light chain (NfL), glial
fibrillary acidic protein (GFAP), total tau (t-tau) and ubiquitin C-terminal hydrolase
L1(UCHL1) as biomarkers in FRDA. Additionally, NfL measurements derived from the
novel multiplex assay were compared to those from an established NfL singleplex assay.
Methods: In this study, an ultrasensitive Single molecule array (Simoa) 4-plex assay was
used for the measurement of plasma NfL, GFAP, t-tau, and UCHL1 in 33 FRDA patients
and 13 age-matched controls. Differences in biomarker concentrations between these
groups were computed and associations with genetic and disease related parameters
investigated. Additionally, the agreement between NfL measurements derived from the
4-Plex and an established Simoa NfL singleplex assay was assessed.
Results: Mean plasma NfL, GFAP and UCHL1 levels were significantly higher in FRDA
patients than in controls (NfL: p < 0.001; GFAP: p = 0.006, and UCHL1: p = 0.020).
Conversely, there was no significant difference in concentrations of t-tau in the patient
and control group (p = 0.236). None of the proteins correlated with the GAA repeat
length or the employed measures of disease severity. The individual NfL values derived
from the two assays showed a strong concordance (rc = 0.93). Although the mean
difference of 1.29 pg/mL differed significantly from 0 (p = 0.006), regression analysis did
not indicate the presence of a proportional bias.
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Conclusion: This is the first study demonstrating that NfL, GFAP, and UCHL1 levels are
raised in FRDA, potentially reflecting ongoing neuronal degeneration and glial activation.
Further studies are required to determine their role as marker for disease activity
and progression. Furthermore, the novel 4-plex assay appears to be a valid tool to
simultaneously measure brain-derived proteins at extremely low concentrations in the
peripheral circulation.
Keywords: biomarkers, Friedreich’s ataxia, neurofilament-light chain, glial fibrillary acidic protein, tau, ubiquitin
C-terminal hydrolase L1
INTRODUCTION
Friedreich’s ataxia (FRDA) is the most common autosomal
recessive ataxia worldwide, affecting 1 in 20,000 Caucasians
(Ruano et al., 2014). In the majority of patients, it is caused by a
homozygous guanine-adenine-adenine (GAA) expansion located
in the first intron of the frataxin (FXN) gene (Campuzano et al.,
1996). This leads to a deficiency of the mitochondrial protein
FXN that in turn causes degeneration in the dorsal root ganglia,
spinocerebellar, and corticospinal tracts and the cerebellar
dentate nucleus (Koeppen et al., 2017). This pattern ultimately
gives rise to the complex clinical phenotype characterized by a
progressive mixed sensory and cerebellar ataxia with depressed
reflexes, limb weakness, and impaired proprioception (Parkinson
et al., 2013). The clinical presentation is often complicated by
the high incidence of skeletal deformities, insulin resistance, and
cardiac dysfunction (Delatycki and Corben, 2012). In addition
to the damage in neurons, cardiac myocytes, and pancreatic
beta-cells, there is a growing number of evidence indicating
that FXN mutations also cause astrocyte impairment (Loriìa and
Diìaz-Nido, 2015; Franco et al., 2017).
Given the advances in the understanding of the pathogenesis
of FRDA (Cook and Giunti, 2017), and the consequently rapidly
expanding therapeutic pipeline (Rummey et al., 2018), there is
an increasing need to measure disease progression and monitor
drug effects reliably and objectively. Previous trials have been
mainly reliant on clinical measurements, which are susceptible
to inter-rater variability and limited by their poor ability to detect
disease progression in this slowly progressive disease (Bürk et al.,
2009). The Food and Drug Administration defines biomarkers
as objectively measurable characteristics that are indicators of
physiological and pathological processes or reflect response
to therapeutic interventions (Biomarkers Definitions Working
Group, 2001). Over the past decade, several brain-derived
proteins have emerged as promising candidate markers for
neurodegeneration in a variety of acute and chronic neurological
diseases (Zetterberg et al., 2013; Burman et al., 2014; Benninger
et al., 2016; Byrne et al., 2017). These include the astrocytic
intermediate filament protein, glial fibrillary acidic protein
(GFAP) (Yang and Wang, 2015); the neuron-specific cytoskeletal
protein neurofilament-light chain (NfL) (Liu et al., 2004); a
Abbreviations: CSF, Cerebrospinal fluid; FRDA, Friedreich’s ataxia; FXN, frataxin;
GFAP, glial fibrillary acidic protein; N4PA, Neurology A 4-Plex assay; NfL,
Neurofilament-light chain; NFLA, Neurofilament-light singleplex assay; SARA,
Scale for the Assessment and Rating of ataxia; Simoa, Single-molecule array; T-tau,
total tau; UCHL1, ubiquitin carboxy-terminal hydrolase L1.
cytoplasmatic neuronal enzyme, ubiquitin C-terminal hydrolase
L1 (UCHL1) (Wilkinson et al., 1989); and the microtubule
associated protein tau (Binder et al., 1985). While NfL, total tau
(t-tau) and UCHL1 are recognized as markers for neuroaxonal
damage (Kawata et al., 2016), increased GFAP levels reflect
astrocyte activation or injury (Yang and Wang, 2015; Figure 1).
These proteins are released into the extracellular space after
neuronal or glial injury and subsequently detectable in the
cerebrospinal fluid (CSF). The development of ultrasensitive
immunoassays now allows the quantification of these proteins
at extremely low abundance in the peripheral circulation (Rissin
et al., 2010). Moreover, the introduction of multi-analyte, or
multiplex, assays enables the simultaneously quantification of
multiple proteins within one experiment. However, multiplex
assay have not been adopted widely as concerns remain regarding
the potential interference between different antibodies, analytes
or assay reagents (Tighe et al., 2015).
Considering that the nervous system is the predominantly
affected tissue in FRDA, the investigation of brain-enriched
proteins reflecting damage to different central nervous
system cell types appeared as a promising approach of
biomarker research in this disease. In this study, we aimed
to investigate whether plasma GFAP, NfL, UCHL1 and
t-tau differ in concentration in FRDA compared to age-
matched controls using a novel Single molecule array (Simoa)
multiplex immunoassay. Furthermore, the promising NfL
results along with the growing body of literature on NfL
as a neurodegeneration marker led us to test the marker




Plasma samples from 33 consecutive patients with genetically
confirmed FRDA enrolled in the European Friedreich’s Ataxia
Consortium for Translational Studies (EFACTS) natural history
study were collected prospectively at the National Hospital
for Neurology and Neurosurgery, London, between January
and March 2018. The 13 age- and gender-matched controls
were selected from the control population. The control subjects
had no clinical evidence of neurological disease. Both studies
were approved by the local ethics committee (REC Number:
10/H0716/51; REC Number: 17/LO/0381). All participants
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FIGURE 1 | Neuronal and glial biofluid markers of neurodegeneration. The
glial fibrillary acidic protein (GFAP) is the main structural protein in astrocytes.
The neurofilament-light chain protein (NfL) reflects damage to large-caliber
myelinated axons. The microtubule binding protein tau is preferentially
localized within thin, non-myelinated axons. The ubiquitin C-terminal hydrolase
L1 (UCHL1) is one of the most abundant proteins in the central nervous
system and localized mainly in neuronal cytoplasm.
provided written informed consent in accordance with the
Declaration of Helsinki.
Demographical data (age and gender) was documented for
patients and controls. The 40-point semi-quantitative Scale for
the Assessment and Rating of ataxia (SARA) (Schmitz-Hübsch
et al., 2006) was obtained at the day of the sample collection
by clinicians experienced in the scoring of this clinical scale.
Disease duration, expressed as difference between age at sample
collection and age at symptom onset in years, was used as an
additional surrogate parameter for disease severity. The presence
of clinical signs of neuropathy, namely impaired vibration sense
and reduced limb reflexes, were abstracted from the relevant
subsections of the Inventory of Non-Ataxia Signs (Jacobi et al.,
2013). If either one of these subsections was positive, the patient
was recorded to have positive clinical signs of neuropathy. The
GAA repeat size was abstracted from the EFACTS database.
Measurement of Plasma Biomarkers
EDTA plasma samples were collected from unfasted participants,
processed within one hour of collection and stored at
−80◦C. Two microcentrifuge tubes were stored for each
participant to avoid multiple freeze-thaw cycles. Plasma NfL,
GFAP, UCHL1, and t-tau concentrations were quantified
using the Simoa Human Neurology A 4-Plex assay (N4PA)
(QuanterixTM, Lexington, MA, United States) on a Simoa
HD-1 analyzer (QuanterixTM, Lexington, MA, United States)
according to manufacture guidelines. The lower limits of
detection for the target proteins are 0.104 pg/mL, 0.221 pg/mL,
0.024 pg/mL, and 1.74 pg/mL for NfL, GFAP, t-tau, and
UCHL1, respectively. Additionally, plasma NfL concentrations
were quantified a second time in the patient group with
the Simoa Neurofilament-light assay (NFLA) (QuanterixTM,
Lexington, MA, United States), which has a detection limit of
0.038 pg/mL.
All samples were measured in duplicate by aspirating two
aliquots from a single well. The mean concentration of the
two measurements was used for the analysis. In four patients,
only one measurement could be obtained for each protein
of interest. Given the low intra-sample variation between
duplicate readings for the remaining samples in NfL, GFAP
and t-tau, and the lack of reported problems with the single
measurements, these values were included in the analysis.
Furthermore, the intra-assay coefficient of variation (CV) was
calculated between duplicate readings for each protein. In the
N4PA, the mean CVs were NfL: 5.0%, GFAP: 3.3%, t-tau:
9.0%, and UCHL1: 23.0%. Samples with CVs above 20%
were excluded from further analysis (tau n = 3; UCHL1
n = 16). Biomarker quantification could not be performed
in one patient sample, possibly due to a high lipid content
as suspected in the initial visual inspection. The mean CV
in the NFLA was 4.2%, with no sample exceeding the CV
threshold.
Statistical Analysis
Descriptive statistics consisted of mean and standard deviation
(SD) for normally distributed continuous variables and median
and interquartile range (IQR) for skewed continuous variables.
All variables were examined for normality with distributional
plots and the Shapiro–Wilk test. As biomarker levels were
not normally distributed, natural log-transformation was
performed and produced normal distribution of all biomarker
values. For the simplicity of notation, the original values were
used in the text, figures, and tables. The independent Student
t-test and the Mann–Whitney U-test were used to test for
inter-group differences for transformed and raw biomarker
levels, respectively. The Pearson’s chi-square test was used to
assess between-group differences for categorical variables. The
relationship between age and biomarker levels was assessed
with the Spearman’s correlation coefficient (rs). Associations
between disease-related parameters and biomarker levels were
computed with multiple linear regressions adjusted for age.
Due to the significant number of cases for which a GAA
repeat size was not available, the relationship between GAA
repeat length and transformed biomarkers were computed
separately using Pearson’s partial correlations controlling
for age. Patients who were heterozygote for a FXN point
mutation and a GAA repeat expansion were excluded from
the correlation test using GAA repeat length. The agreement
between log-NfL levels obtained from the N4PA and NFLA
was investigated using the Lin’s concordance coefficient. The
agreement between the two measurements was visualized
by constructing a Bland–Altman plot. Linear regression was
used to identify the presence of a proportional bias. All tests
were two-sided with a threshold for statistical significance
set at p < 0.05. Analysis was first performed including two
major outliers and repeated after their exclusion to evaluate
their influence. Their exclusion did not affect any statistical
significances. The statistical analysis was carried out using
SPSS Statistics 25.0 (IBM Corporation, NY, United States)
and GraphPad Prism 9.4 (The MathWorks Inc., MA,
United States).
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RESULTS
Comparison of Biomarker
Concentrations Between Patients and
Controls
A total of 46 subjects consisting of 33 individuals with
FRDA and 13 healthy controls were enrolled. An overview
of demographic and clinical characteristics of the groups is
provided in Tables 1, 2. The study population was predominantly
female (59%), with a median age of 35.50 (IQR: 24.75–46.50)
years. There was no statistically significant difference in age
(p = 0.825) or gender (p = 0.675) between controls and patients.
The median age of onset was 13 (7.50–22.50) years, with six
(18%) individuals classifying as late-onset (>25 years) FRDA.
The mean total SARA score (±SD) was 20.44 ± 7.40. The SARA
score correlated directly with the disease duration (rs = 0.57,
p < 0.001). The genetic dataset in the EFACTS database was
available for 24 (72.3%) patients. Two of these patients were
compound heterozygote, harboring a point mutation on one
FXN allele and an expanded GAA repeat on the other. The
remaining patients were homozygous for expanded GAA repeats.
All patients had clinical signs of neuropathy at the time of sample
collection.
In order to identify possible confounding effects of
demographic factors on biomarker values, the relationship
between age and gender with protein levels was computed. There
was a significant positive association between GFAP levels and
age in the patient group (rs = 0.626, p < 0.001), but not in the
control group (rs = 0.12, p = 0.712). Conversely, NfL values
correlated directly with age in the control group (rs = 0.740,
p = 0.006), but not in the patient group (rs = −0.070, p = 0.707).
Neither UCHL1, nor tau levels showed an association with age
in either subject group. There was no difference in biomarker
concentrations between male and female participants.
Plasma NfL and GFAP concentrations were significantly
higher in FRDA patients than in controls (17.10 vs. 7.61 pg/mL,
p < 0.001 and 99.00 vs. 59.50 pg/mL, p = 0.006, respectively).
FRDA patients also had significantly higher UCHL1
concentrations compared to the control group (14.79 vs.
5.07 log pg/mL, p = 0.020). Conversely, t-tau levels did not differ
between patients and controls (1.33 vs. 2.08 pg/mL, p = 0.236)
(Figure 2 and Table 3).
Association of Biomarkers With
Measures of Disease Severity
Multiple linear regressions adjusted for age were used to model
the relationship between the SARA score and the disease
TABLE 1 | Demographics.
Controls FRDA P value
Gender
Male 6 (46.2%) 13 (39.4%) 0.675
Female 7 (53.8%) 20 (60.6%)
Age (years) 37 (29.00–42.50) 34 (23.50–40.00) 0.825
Data are shown as median (interquartile range) or absolute number (%).
duration with biomarker concentrations (outcome). A significant
regression equation was found for GFAP concentrations
[F(3,27) = 11.43, R2 = 0.51, and p < 0.001]. The regression
equation showed that only age was a significant predictor of
GFAP levels (standardized ß-coefficient = 0.60, p < 0.003). No
other significant associations were found. Plasma concentrations
of the four biomarkers did not correlate with the GAA repeat
size of either FXN allele as assessed by partial rank correlations
controlling for age.
Correlation Between Plasma Markers
Among the four biomarkers studied, transformed GFAP and NfL
values showed a positive linear relationship in the patient group
while controlling for age (r = 0.64, p < 0.001) (Figure 3). In
the control group, there were no significant associations among
biomarker values.
Comparison of NfL Values Derived From
the N4PA and NFLA
Samples were included for which NfL values had been obtained
from both assays (n = 31). The median NfL values were
14.26 (11.31–19.37) pg/mL and 12.43 (9.41–18.71) pg/mL for
the N4PA and the NFLA, respectively. The mean difference
of 1.37 ± 2.60 pg/mL differed statistically significant from 0
based on a one-sample t-test (p = 0.006). The Lin’s concordance
correlation coefficient showed a very strong concordance
between the individual transformed NfL values derived from the
two assays (rc = 0.93, 95% CI: 0.78–0.94) (Figure 4A). A Bland–
Altman plot was constructed by plotting the differences against
the average NfL values (Figure 4B). The graph indicates that
the magnitude of the difference is similar across the range of
measured plasma concentrations. This is supported by a linear
regression model with the difference of the measurements as
dependent and the mean NfL value as independent variable
[ß =−0.15, F(1,29) = 3.14, and p = 0.087].
DISCUSSION
This study represents the first investigation of plasma markers
of neurodegeneration in FRDA. Using the ultrasensitive Simoa
technology, we showed that the brain-derived proteins NfL,
GFAP, and UCHL1 are significantly raised in FRDA compared to
aged-matched controls. Furthermore, it was demonstrated that
NfL concentrations derived from the novel N4PA show a strong
concordance with those obtained from a well-established NfL
singleplex assay. Several conclusions can be drawn from this
study, with implications beyond the field of FRDA.
Firstly, our results indicate that the Simoa N4PA has a
comparable analytic performance to the Simoa NFLA concerning
the measurement of plasma NfL. Previous concerns about
multiplex immunoassays evolved mainly around technical
challenges, including the interferences of multiple reagents,
cross-reactivity between different antibodies and the vast
dynamic range of biological proteins (Kingsmore, 2006). To the
best of our knowledge, only one study has previously published
results using the N4PA in a cohort of 107 adults with traumatic
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TABLE 2 | Summary of clinical characteristics.
N Patients Mean ± SD Range
AOO (years)∗ 33 13 (7.50–22.50) 2–51
Disease duration (years)∗ 33 18 (12.00–25.00) 6–61
GAA1 size# 24 584.40 ± 64.55 150–1200
GAA2 size# 24 817.20 ± 54.17 534–1200
SARA score 33 20.44 ± 7.40 6.50–33.00
Neuropathy 33 33 (100%) –
‘∗’ Median and interquartile range are given for these variables due to skewed distribution. ‘#’ Patients who were heterozygote for a FXN point mutation and a GAA
expansions were excluded from this analysis. AOO, Age of onset. SARA, Scale for the Assessment and rating of ataxia. GAA1, FXN allele with the shorter GAA repeat
length. GAA2, FXN allele with the longer GAA repeat length.
FIGURE 2 | Comparison of plasma levels of four brain-derived proteins
between FRDA patients and controls. Plasma concentrations of (A) NfL,
(B) GFAP, and (C) ubiquitin C-terminal hydrolase L1 (UCHL1) are significantly
increased in FRDA compared to age-matched controls. (D) Plasma tau levels
were lower in FRDA patients, although this did not reach statistical
significance. The horizontal bars indicate the median with error bars denoting
the interquartile range. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
brain injury (Korley et al., 2018). Korley et al. (2018) reported a
strong correlation between these two assays with a small mean
difference. Indeed, the mean difference of 1.37 pg/mL observed
TABLE 3 | Intergroup comparison of plasma biomarker levels.
Biomarker (pg/mL) Controls Patients
NfL 7.61 (6.18–11.18) 17.10 (13.00–24.40)
GFAP 59.50 (49.75–86.88) 99.00 (76.50–149.00)
T-tau 2.08 (1.25–2.91) 1.33 (0.92–2.03)
UCHL1 5.07 (3.33–7.55) 14.79 (7.96–31.50)
Median (interquartile range) biomarker levels of untransformed data in the control
and the patient group are outlined. Neurofilament-light (NfL), glial fibrillary acidic
protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCHL1) were significantly
raised in FRDA patients compared to controls.
in our patient population is comparable to the 1.87 pg/mL
reported in their study. Although Bland–Altman plots are
useful in the assessment of agreements between two quantitative
measurement methods, it is important to note that the plots do
not imply whether the constructed 95% limits of agreements
are acceptable in clinical practice (Giavarina, 2015). This range
must be defined according to clinical and research necessities
in the specific setting. Considering the potential use of NfL to
monitor the severity and progression in FRDA, the magnitude
of the difference appears to be in a range that is unlikely to be
of great significance. However, although our analysis did not
reveal the presence of a proportional bias, Korley et al. (2018)
reported a greater difference with increasing NfL values, most
evidently above 100 pg/mL. The discrepancy between the two
studies may be explained by the limited range of NfL values
observed in FRDA, which did not exceed 38.7 pg/mL. Therefore a
validation of the N4PA assay across a wider concentration range
is required.
Secondly, given the complex neuropathology of FRDA and
the lack of studies investigating brain-specific proteins as
dynamic markers of central nervous system disease progression,
the simultaneous measurement of multiple proteins may be
beneficial. The N4PA allows the detection of NfL, GFAP, UCHL1,
and t-tau in plasma volumes as little as 140 µL in parallel
using paramagnetic beads with different coded dye-labels for
the four target analytes (Wilson et al., 2016). This yields several
advantages, including the need for smaller sample volumes,
minimization of processing times, and cost savings. Therefore,
it can be hypothesized that the quantification of several proteins
in one single experiment could surge the discovery of biofluid
markers in FRDA and beyond.
In the present study, the concomitant increase of markers
for neuroaxonal damage and astrocytic involvements suggests
the presence of non-cell autonomous processes in FRDA. In the
last decade research on hereditary neurodegenerative disorders
has shifted from a neuron-centric view toward the recognition
of destructive mechanisms arising from central nervous system
glial cells, which likewise express the respective mutant proteins
(Lobsiger and Cleveland, 2007; Phatnani and Maniatis, 2015).
Consistent with this hypothesis, a parallel rise of neuronal and
glial markers has been reported in other neurodegenerative
diseases, such as amyotrophic lateral sclerosis (Benninger et al.,
2016). Specifically in FRDA, dysfunction in glial cells, most
importantly astrocytes, has recently gained increasing attention.
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FIGURE 3 | The relationship between transformed biomarker concentrations in the patient group. (A–F) Partial correlation controlling for age are shown. The
relationship between NfL and GFAP values was significant. ∗∗∗p < 0.001.
First evidence of glial contribution to the nervous system
pathology was provided by a Drosophila model which displayed
FRDA-like symptoms and a reduced life-span after targeted
suppression of FXN in glial cell lines (Navarro et al., 2010).
More recently, Loriìa and Diìaz-Nido (2015) demonstrated that
FXN knock-down in human astrocytes induces mitochondrial
dysfunction, enhances cell death and disrupts neuron–glial
interactions in vitro. This is supported by a time-dependent
effect of FXN deficiency on growth and survival of developing
cerebellar, but intriguingly not forebrain, astrocytes in a fly and
a mouse model (Franco et al., 2017). Thus, elevated plasma
GFAP could serve as a useful marker reflecting in vivo astrocyte
pathology as a contributing factor to cerebellar dysfunction in
FRDA.
The presence of raised plasma NfL levels in FRDA indicates
white matter involvement, as NfL is primarily a marker of white
matter axonal damage (Yuan et al., 2012). This is consistent
with neuropathology reports describing degeneration of the
white matter tracts in the spinal cord, brainstem and cerebellum,
while the cerebral and cerebellar hemispheres remain largely
intact (Koeppen and Mazurkiewicz, 2013). Moreover, although
structural imaging is normal in the early stages of FRDA
(Mascalchi, 2013), recent developments in neuroimaging
modalities such as diffusion-weighted imaging have revealed
white matter changes in cerebral regions where FXN deficiency
causes damage without producing significant atrophy (Pagani
et al., 2010; Rizzo et al., 2011). Notably, in contrast to most
neurodegenerative diseases in which elevated NfL levels have
been described, FRDA patients almost invariably develop
a sensory peripheral neuropathy characterized by deficient
myelination primarily in large myelinated axons (Morral et al.,
2010). Knowing that NfL is also expressed in the peripheral
nervous system (Trojanowski et al., 1986), it is not surprising
that elevated plasma NfL levels have recently been reported in
peripheral neuropathies without central nervous involvement
(Bischof et al., 2017; Sandelius et al., 2018). This raises the
question whether the increase in plasma NfL in FRDA is
predominately caused by the peripheral or the central nervous
system involvement. The investigation of a possible concomitant
elevation of other neuronal-specific intermediate filament
proteins, such as peripherin and α-internexin, might assist
in answering this question. Peripherin and α-internexin are
considered as the fourth subunits of the neurofilament multimer
in the mature nervous system (Zhao and Liem, 2016). As the
name suggests, peripherin is predominantly expressed in the
peripheral nervous system, while α-internexin is found in the
central nervous system. These intermediate filament proteins
have not been investigated as biofluid markers yet. In our
cohort, all patients displayed clinical signs of neuropathy. This
unfortunately meant that a comparison between a group with
and without peripheral pathology was not possible.
In addition to elevated levels of plasma NfL, we also
observed increased concentrations of UCHL1. UCHL1 is highly
specific to neurons (Day and Thompson, 2010), where it is
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FIGURE 4 | Comparison between NfL measurements derived from the 4-Plex and NfL singleplex assay | (A) Individual log-transformed NfL from the 4-Plex and NfL
singleplex were plotted against each other. Lin’s concordance correlation coefficient (rc) evaluates the degree to which pairs of measurements fall on the 45◦ line,
here represented as the discontinuous line, through the origin. (B) Bland–Altman Plot. Each patient sample is represented as a point on the graph. The difference
between the two measurements (Neurology 4-Plex assay – Neurofilament-light singleplex assay) is plotted against the mean of the two measurements [(Neurology
4-Plex assay + NfL singleplex assay)/2]. The mean difference (1.37 pg/mL) is represented by the black line. The upper (6.48 pg/mL) and lower (−3.74 pg/mL) 95%
agreement intervals, designated with discontinuous lines, are shown. These statistical limits were computed using the mean and the standard deviation (2.60 pg/mL)
of the differences between two measurements.
involved in the ubiquitin-proteasome pathway (UPP) that is
crucial for the degrading of intracellular proteins, such as FXN
(Rufini et al., 2011). Although UCHL1 has been suggested as
a nonspecific maker for neurodegeneration, Öhrfelt et al. (2016)
have hypothesized that elevated UCHL1 concentrations could
also reflect disturbed proteasomal degeneration. Although
UCHL1 has not been specifically studied in FRDA, the expression
of enzymes involved in the UPP may be altered due to the
degradation of FXN. Therefore, a more detailed characterization
of proteins involved in FXN degradation might provide answers
to the question whether increased UCHL1 levels in FRDA
reflect an altered expression of this protein or non-specific
neuronal damage. Moreover, biomarkers involved in the UPP
could serve especially useful in FRDA considering that several
promising targets within the UPP system have recently been
explored in preclinical studies (Rufini et al., 2015; Benini et al.,
2017).
Interestingly, the elevation of these markers of neuroaxonal
damage was not accompanied by a corresponding increase of
t-tau. Differences between these markers may indicate distinct
predilection for sites and mechanisms of axonal injury in
FRDA. While UCHL1 represents one of the most abundant
central nervous system proteins (Bishop et al., 2016) and NFL
is primarily expressed in large-caliber myelinated axons, t-tau
is regarded as a marker for damage to thin, unmyelinated
axons (Yilmaz et al., 2017). These unmyelinated axons are not
specifically vulnerable in FRDA (Koeppen and Mazurkiewicz,
2013). Therefore, the lack of changes of tau in FRDA patient
blood is not surprising. Moreover, clearance mechanism of tau
in the peripheral circulation may complicate its interpretation
in slowly progressive neurological disease, such as FRDA
(Zetterberg et al., 2013). These degrading mechanisms might
explain seemingly inconsistent reports regarding the relationship
between t-tau levels measured in plasma and in CSF. While
good correlations have been described in acute or rapidly
progressive neurological diseases (De Vos et al., 2017; Kovacs
et al., 2017), weak or absent correlations have been reported in
slowly progressive neurodegenerative disorders (Zetterberg et al.,
2013; Mattsson et al., 2016).
With the main objective of biomarker research in FRDA
being focused on identifying markers of disease progression,
we investigated the relationship between clinical markers for
disease severity with biomarker concentrations. In our FRDA
cohort, no significant relationship was observed between disease
duration or the SARA score with biomarker levels after adjusting
for age. GFAP values initially appeared to be correlated with
longer disease duration. However, when we adjusted the multiple
regressions to control for age, this correlation no longer
significant. This suggests that in our cohort GFAP levels were
associated mainly with age rather than with disease duration.
Similar observations have previously been made in a small cohort
of spinocerebellar ataxia patients, and it has been suggested that
GFAP may not only be marker of astrocytic damage, but instead
also a marker of astrocyte activation (Shi et al., 2015). This
would explain why concentrations do not change in parallel with
the neurodegenerative process. Another possible explanation
for the lack of correlation with disease severity markers could
be the small sample size and the relatively homogeneity of
our patient cohort regarding disease duration, with more than
50% of patients having a disease duration between 10 and
19 years.
Indeed, the two most important limitations of this study are
its moderate cohort size, especially the low number of controls,
and the limited range of disease severity across the cohort. Even
though no significant correlation between clinical measurements
of disease severity with biomarker levels was observed in this
FRDA population, this could be a result of decreased power
secondary to these limitations. Moreover, although the analytic
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performance of the N4PA in measuring NfL was compared to a
well-established singleplex assay, we have not yet compared the
measurements of the three other proteins to reference assays.
Thus, it is clear that no statements can be made about the analytic
sensitivity regarding GFAP, t-tau and UCHL1. It is especially
clear that further studies are necessary to evaluate the analytic
performance of the 4-plex assay in measuring UCHL1 as this
protein displayed a considerable higher mean intra-assay CV of
23%, with 16 out of 46 samples being excluded on the basis of not
meeting the predefined CV threshold. This observation mirrors
the findings from N4PA measurements in a spinocerebellar ataxia
type three cohort at our institute (personal communication P
Giunti) and undoubtedly requires further investigation.
CONCLUSION
This study provides the first assessment of plasma markers of
neurodegeneration in FRDA, illustrating that NfL, GFAP, and
UCHL1 are significantly raised in FRDA compared to aged-
matched control. These observations may serve as the basis of
further exploration of these brain-derived proteins as promising
biomarkers in FRDA. In addition, we show for the first time
in vivo an increase of GFAP reflecting astrocyte activation.
This is confirmatory of in vitro studies suggesting a role of
astrocytes in FRDA pathology. Finally, UCHL1 increase may
reflect non-specific neuronal damage or alterations in the UPP.
Future studies are needed to confirm our findings and determine
whether, when applied to more heterogeneous cohorts, they serve
as useful markers of disease severity.
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